Alkeran

(melphalan)

ApprovedSmall molecule

Melphalan is a chemotherapy drug used to treat certain blood cancers, including multiple myeloma (cancer of blood cells in the bone marrow) and some types of lymphoma. It works by damaging cancer cell DNA to stop them from growing.[2] Alkeran is currently approved and in use across 84 indications[4].[1]

Alkeran is one of 1476 small molecule programs targeting Non-Hodgkins Lymphoma. It is currently in Approved.

Indications

591

Total Trials

Active Trials

1,475

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Non-Hodgkins LymphomaActive, not recruiting

Primary Systemic AmyloidosisActive, not recruiting

Primitive Neuroectodermal TumorActive, not recruiting

MacroglobulinemiaActive, not recruiting

Aplastic AnemiaActive, not recruiting

ToxicityActive, not recruiting

Unspecified Peripheral T-Cell LymphomaApproved

T-Cell Non-Hodgkin LymphomaActive, not recruiting

SuicideActive, not recruiting

Anaplastic Large Cell LymphomaActive, not recruiting

Non-Hodgkins LymphomaApproved

Active, not recruiting

Primary Systemic AmyloidosisPhase 3

Active, not recruiting

Primitive Neuroectodermal TumorPhase 1

Active, not recruiting

MacroglobulinemiaPhase 2

Active, not recruiting

Aplastic AnemiaPhase 2/Phase 3

Active, not recruiting

ToxicityPhase 1

Active, not recruiting

Unspecified Peripheral T-Cell LymphomaApproved

Approved

T-Cell Non-Hodgkin LymphomaPhase 1

Active, not recruiting

SuicidePhase 1/Phase 2

Active, not recruiting

Anaplastic Large Cell LymphomaPreclinical

Active, not recruiting

Showing 10 of 84 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Alkeran

AApotex Inc.

Approved

8 2

Halaven

Eisai

Preclinical

38 3

Trodelvy

Gilead

Preclinical

37 4

DATROWAY

Daiichi Sankyo

Preclinical

4 5

MS Contin

Merck & Co.

Preclinical

2 6

Blenoxane

Bristol-Myers Squibb

Preclinical

1 7

Voltaren

Novartis

Preclinical

1 8

Tricor

JJagotec

Preclinical

1 9

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 10

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Neuroblastoma

NCT02605421

Phase 1/2Active, not recruiting

Multiple Myeloma

NCT01054196

Q4 2027

Phase 2Active, not recruiting

Maintenance Therapy

NCT03004287

Phase 2Recruiting

Multiple Myeloma

NCT06140966

Q2 2028

Phase 2Not yet recruiting

Acute Myeloid Leukemia

NCT06954987

Phase 1Recruiting

Acute Lymphoblastic Leukemia

NCT06287944

Clinical

Trials by Indication[1]

Multiple Myeloma46 trials

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00040937·147 enrolled

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 3·NCT01818752·955 enrolled

Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma

Completed· Takeda logo

Takeda·Phase 1/2·NCT01335685·61 enrolled

Show 43 more trials

Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma

Completed·—·Phase 2·NCT00004088·77 enrolled

Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00002556·312 enrolled

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Withdrawn·SSWOG Cancer Research Network·Phase 2·NCT01055301

High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant

Terminated·UUniversity of Southampton·Phase 2·NCT00637767·25 enrolled

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003401

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06140966·54 enrolled

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06207799·40 enrolled

Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)

Completed·NNantes University Hospital·Phase 1/2·NCT01279694·72 enrolled

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT00005792·131 enrolled

Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients

Terminated·FFondazione EMN Italy Onlus·Phase 2·NCT01116128·8 enrolled

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

Terminated·HHackensack Meridian Health·Phase 2·NCT01453088·63 enrolled

MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning

Completed·PPETHEMA Foundation·Phase 2·NCT00564200·30 enrolled

High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy

Unknown status·—·Phase 3·NCT00747877·460 enrolled

Autologous Transplant for Multiple Myeloma

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00177047·363 enrolled

Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT02474563·171 enrolled

Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00028600·60 enrolled

Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma

Completed·WWen-Kai Weng·Phase 2·NCT00185614·63 enrolled

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT02728102·203 enrolled

Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00003954·40 enrolled

Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01045460·36 enrolled

Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT00566098·26 enrolled

Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00313625·20 enrolled

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Completed·MMayo Clinic·Phase 1·NCT00477815·30 enrolled

Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 1/2·NCT00334932·32 enrolled

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00006244·36 enrolled

Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma

Terminated·MMayo Clinic·Phase 2·NCT00635024·1 enrolled

Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant

Recruiting·WWashington University School of Medicine·Phase 1·NCT06523699·30 enrolled

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003399

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT02780609·22 enrolled

Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma

Terminated·BBasque Health Service·Phase 4·NCT02773550·24 enrolled

Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma

Unknown status·RRiverside Haematology Group·Phase 3·NCT00003603·660 enrolled

RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT01251172

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT02440464·57 enrolled

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00014508

TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01039025·60 enrolled

Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study

Active, not recruiting·WWeill Medical College of Cornell University·Phase 1/2·NCT01054196·52 enrolled

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00002678·595 enrolled

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

Active, not recruiting·UUniversity of Turin, Italy·Phase 4·NCT03829371·450 enrolled

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02195479·706 enrolled

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00911859·118 enrolled

TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)

Completed·UUniversity of Illinois at Chicago·Phase 1·NCT02043847·12 enrolled

Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Active, not recruiting·—·Phase 2·NCT03346135·31 enrolled

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

Completed·HHackensack Meridian Health·Phase 1/2·NCT00784823·32 enrolled

Lymphoma20 trials

Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT02701673

CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT04690192·30 enrolled

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002982

Show 17 more trials

Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT00080886·68 enrolled

High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00669812·60 enrolled

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT02130869·8 enrolled

GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma

Terminated·AAHS Cancer Control Alberta·Phase 1/2·NCT02295722·100 enrolled

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Suspended·—·Phase 2·NCT06692452·24 enrolled

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03259503·50 enrolled

Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)

Completed·SSoonchunhyang University Hospital·Phase 2·NCT03792815·51 enrolled

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT01625351·23 enrolled

Combination Chemotherapy in Treating Patients With Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00002835·116 enrolled

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

Completed·WWeill Medical College of Cornell University·Phase 1/2·NCT02059239·34 enrolled

Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·NNorthwestern University·Phase 1·NCT00058292·44 enrolled

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

Completed·SSwiss Cancer Institute·Phase 3·NCT00003215·400 enrolled

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Unknown status·SSichuan University·Phase 3·NCT05466318·306 enrolled

Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease

Completed·—·N/A·NCT01702961·75 enrolled

VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)

Unknown status·SSamsung Medical Center·Phase 2·NCT02544425·27 enrolled

Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01538472·40 enrolled

Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 2·NCT00025064·260 enrolled

Stem Cell Transplant9 trials

Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

Completed·WWeill Medical College of Cornell University·Phase 2·NCT02497404·40 enrolled

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Active, not recruiting·—·Phase 2·NCT00544115·260 enrolled

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT02483000·3 enrolled

Show 6 more trials

Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib

Terminated·—·Phase 3·NCT02489500·3 enrolled

2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)

Withdrawn·UUniversity of Arkansas·Phase 2·NCT03003728

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT02114502

Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00357396·10 enrolled

Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer

Terminated·UUniversity of California, San Francisco·N/A·NCT00301860·8 enrolled

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Active, not recruiting·DDiane George·Phase 1/2·NCT02061800·14 enrolled

Neuroblastoma7 trials

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT02605421·12 enrolled

Therapy for Children With Advanced Stage Neuroblastoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01857934·153 enrolled

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Completed·CChildren's Oncology Group·Phase 1·NCT01175356·99 enrolled

Show 4 more trials

Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma

Completed·—·Phase 3·NCT00002802·500 enrolled

Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma

Completed·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00365755

Chemotherapy in Treating Children With Neuroblastoma

Completed·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1·NCT00002730

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Completed·CChildren's Oncology Group·Phase 1·NCT01798004·150 enrolled

Hematologic Malignancies6 trials

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

Withdrawn·BBaptist Health South Florida·Phase 2·NCT04282174

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Completed·SSally Arai·Phase 1·NCT00477035·22 enrolled

Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

Unknown status·XXinqiao Hospital of Chongqing·Phase 1·NCT04264039·30 enrolled

Show 3 more trials

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Completed·RRoswell Park Cancer Institute·Phase 2·NCT01529827·94 enrolled

Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT01745913·2 enrolled

Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

Unknown status·XXinqiao Hospital of Chongqing·Phase 1·NCT04264078·30 enrolled

76 more indications

Primary Systemic Amyloidosis4 trials

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

Completed·SSWOG Cancer Research Network·Phase 2·NCT00064337·104 enrolled

Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Completed·MMayo Clinic·Phase 3·NCT00477971·89 enrolled

Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00089167

Show 1 more trial

Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Completed·—·Phase 2·NCT00790647·10 enrolled

Stem Cell Transplantation4 trials

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03615105·9 enrolled

Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma

Unknown status·MMedical Research Council·Phase 3·NCT00002599·750 enrolled

Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy

Completed·AAustrian Forum Against Cancer·Phase 3·NCT00205764·212 enrolled

Show 1 more trial

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma

Completed·—·Phase 2·NCT00002601·13 enrolled

Leukemia3 trials

CD34+ Transplants for Leukemia and Lymphoma

Not yet recruiting·GGuenther Koehne·Phase 2·NCT05565105·100 enrolled

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00055653

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT03856216·15 enrolled

Myelodysplastic Syndrome3 trials

CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome

Suspended·GGuenther Koehne·Phase 2·NCT05617625·50 enrolled

Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation

Active, not recruiting·—·Phase 2·NCT04339101·59 enrolled

Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002989·207 enrolled

Transplantation3 trials

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01010217·176 enrolled

Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation

Not yet recruiting·TTechnische Universität Dresden·Phase 2·NCT07025824·220 enrolled

NK Cells in Cord Blood Transplantation

Unknown status·MM.D. Anderson Cancer Center·Phase 1·NCT01619761·13 enrolled

Myelofibrosis3 trials

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03426969·3 enrolled

Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis

Withdrawn·—·Phase 1·NCT02528877

Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

Completed·—·Phase 1·NCT02917096·18 enrolled

Germ Cell Tumor3 trials

Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor

Unknown status·SSamsung Medical Center·Phase 2·NCT02784054·25 enrolled

Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors

Completed·CChildren's Oncology Group·Phase 2·NCT00002594·31 enrolled

Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors

Unknown status·OOHSU Knight Cancer Institute·Phase 1/2·NCT00983398·17 enrolled

Amyloidosis3 trials

Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis

Completed·NNantes University Hospital·Phase 1/2·NCT00621400·27 enrolled

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Completed·—·Phase 2·NCT01083316·35 enrolled

Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis

Completed·—·Phase 2·NCT00075621·62 enrolled

Acute Myeloid Leukemia3 trials

Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia

Withdrawn·GGuenther Koehne·Phase 1/2·NCT04982354

Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia

Completed·CChildren's Oncology Group·Phase 1·NCT00004056·35 enrolled

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06954987·244 enrolled

Colorectal Cancer3 trials

Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 3·NCT00020501

Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00103298

A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00001576·28 enrolled

Myeloma2 trials

Bendamustine and Melphalan in Myeloma

Completed·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT03187223·120 enrolled

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

Completed·SSWOG Cancer Research Network·Phase 3·NCT00002548·899 enrolled

Hematopoietic Stem Cell Transplant2 trials

A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients

Terminated· Pfizer logo

Pfizer·Phase 1/2·NCT02614560·14 enrolled

Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders

Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT01626092·3 enrolled

Lenalidomide2 trials

Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old

Completed·PPETHEMA Foundation·Phase 3·NCT01916252·460 enrolled

Lenalidomide and High-Dose Melphalan

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01079936·61 enrolled

Acute Lymphoblastic Leukemia2 trials

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Recruiting·—·Phase 1·NCT06287944·15 enrolled

Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·UUniversity College, London··NCT01085617

Melanoma2 trials

A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00001296·122 enrolled

Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma

Withdrawn·—·N/A·NCT02507076

Lymphoid Malignancies2 trials

Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00472056·93 enrolled

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT01921387·20 enrolled

Chemotherapy2 trials

Intra-arterial Chemotherapy for Spinal Metastases

Completed·WWeill Medical College of Cornell University·Phase 1·NCT01637766·12 enrolled

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00936936·64 enrolled

Mantle Cell Lymphoma2 trials

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00006747·4 enrolled

Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Unknown status·GGerman Low Grade Lymphoma Study Group·Phase 3·NCT00016887

Ewing sarcoma2 trials

Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma

Withdrawn·—·N/A·NCT01795430

A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma

Withdrawn·UUniversity of Louisville·Phase 1·NCT01969942

Breast Cancer2 trials

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

Completed·—·Phase 2·NCT00003042·41 enrolled

Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer

Completed·YYale University·Phase 2·NCT00002680·40 enrolled

Myelodysplastic Syndromes2 trials

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Completed·TThe University of New South Wales·Phase 2/3·NCT00454480·2,000 enrolled

Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes

Completed·—·Phase 1·NCT00641030·20 enrolled

Bone Marrow Transplantation2 trials

High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma

Unknown status·LLymphoma Trials Office·Phase 3·NCT00003578·500 enrolled

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00014469

Conditioning2 trials

Two Step Haplo With Radiation Conditioning

Recruiting·TThomas Jefferson University·Phase 2·NCT05031897·63 enrolled

Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03385096·122 enrolled

Aplastic Anemia1 trial

Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07078721·11 enrolled

Stage IV Ovarian Epithelial Cancer1 trial

High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery

Completed·EEBMT Solid Tumors Working Party·Phase 3·NCT00004921

Graft Versus Host Disease1 trial

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00691015·48 enrolled

Liver Cancer1 trial

Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00030082

TED1 trial

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03579875·48 enrolled

Autologous Hematopoietic Stem Cell Transplantation1 trial

Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation

Completed·UUniversity of Alabama at Birmingham·Phase 1/2·NCT01690143·45 enrolled

Maintenance Therapy1 trial

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT03004287·50 enrolled

High Risk1 trial

HSCT for High Risk Inherited Inborn Errors

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00383448·38 enrolled

Exercise1 trial

Effects of Exercise in Combination With Epoetin Alfa

Completed·UUniversity of Arkansas·N/A·NCT00577096·120 enrolled

Central Nervous System Lymphoma1 trial

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003632·30 enrolled

Sickle Cell Disease1 trial

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

Completed·MMonica Bhatia·Phase 1·NCT02867800·24 enrolled

Infusion1 trial

A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients

Terminated·OOncopeptides AB·Phase 2·NCT04412707·27 enrolled

Brain Cancer1 trial

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT04521946

Relapse1 trial

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

Terminated·—·Phase 3·NCT02366663·3 enrolled

Stem Cell1 trial

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00651937·80 enrolled

Hematopoietic Cell Transplantation1 trial

Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation

Terminated·WWashington University School of Medicine·Phase 1·NCT02750254·5 enrolled

Ocular Melanoma1 trial

Melphalan Chemoreduction for Ocular Melanoma

Enrolling by invitation·HHospital das Clínicas de Ribeirão Preto·Phase 1/2·NCT05893654·10 enrolled

Unilateral Retinoblastoma1 trial

Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma

Completed·CChildren's Oncology Group·Phase 1·NCT02097134·14 enrolled

Unresectable Cancer1 trial

A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00001587·30 enrolled

Kidney Transplant1 trial

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

Recruiting·AAlice Bertaina·Phase 1/2·NCT05508009·12 enrolled

Metabolic Disease1 trial

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00003662·90 enrolled

Chronic Myelogenous Leukemia1 trial

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003727·22 enrolled

Myeloid Neoplasm1 trial

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

Completed·UUniversity of Washington·Phase 2·NCT02756572·30 enrolled

Prostate Cancer1 trial

A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)

Terminated·BBarts & The London NHS Trust·Phase 2/3·NCT01907009·29 enrolled

Toxicity1 trial

Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

Completed·UUniversity of Louisville·Phase 1·NCT02472392·10 enrolled

Memory1 trial

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT07052370·30 enrolled

Metastatic Cancer1 trial

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

Recruiting·GGeneral Oncology, Inc.·Phase 1·NCT04150042·24 enrolled

Anemia1 trial

Stem Cell Transplantation for Sickle Cell Anemia

Completed·HHackensack Meridian Health·Phase 3·NCT01877837·30 enrolled

Retinoblastoma1 trial

Conservative Treatments of Retinoblastoma

Active, not recruiting·IInstitut Curie·Phase 2·NCT02866136·133 enrolled

Hematopoietic Cell Transplant1 trial

Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00410982·145 enrolled

Donor1 trial

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Terminated·MMemorial Sloan Kettering Cancer Center·N/A·NCT01598025·3 enrolled

Cutaneous T-cell lymphoma1 trial

Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00506129·33 enrolled

Mesenchymal Stem Cells1 trial

Cord Blood Expansion on Mesenchymal Stem Cells

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00498316·98 enrolled

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00618540·1 enrolled

Patients With Solid Tumors1 trial

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00003926·13 enrolled

Myeloid Malignancies1 trial

Off-the-shelf NK Cells + SCT for Myeloid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT05115630·24 enrolled

AL amyloidosis1 trial

Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis

Completed·NNanjing University School of Medicine·Phase 3·NCT01998503·56 enrolled

Chronic Lymphocytic Leukemia1 trial

Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 2·NCT00276809·30 enrolled

Relapsed or Refractory Hematologic Malignancies1 trial

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02259348·12 enrolled

Malignancies1 trial

Melphalan With BBBD in Treating Patients With Brain Malignancies

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT00253721·21 enrolled

Recurrent or Refractory Solid Tumors1 trial

Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00003899

Peripheral Blood Stem Cell Transplantation1 trial

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT05436418·260 enrolled

Malignant Solid Tumors1 trial

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

Unknown status·MMilton S. Hershey Medical Center·Phase 1·NCT00436761·20 enrolled

Relapsed or Refractory1 trial

Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 2·NCT00025103·75 enrolled

Locally Advanced1 trial

Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs' Girdle

Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT00181025·33 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma

Completed·GGruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie·Phase 2·NCT00556127·94 enrolled

APL1 trial

IS-free Treg HaploHCT

Recruiting·—·Phase 1·NCT04678401·30 enrolled

Hemoglobinopathies1 trial

HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity

Completed·NNorthwell Health·Phase 1/2·NCT02435901·29 enrolled

Dexamethasone1 trial

DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation

Completed·UUniversity of Arkansas·Phase 3·NCT00083915·97 enrolled

Brain Tumors1 trial

Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors

Completed·OOHSU Knight Cancer Institute·Phase 1/2·NCT00303849·33 enrolled

Unspecified2 trials

HD Melphalan and SCT in Patients With IGDD or LCDD

Terminated·—·Phase 2·NCT00681044·5 enrolled

N99-02: Melphalan and Buthionine Sulfoximine

Completed·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1·NCT00005835·31 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

ALKERAN

NDA NDA014691

Nov 18, 1992

ALKERAN

NDA NDA020207

Mar 10, 2016

EVOMELA

NDA NDA207155

Aug 14, 2023

HEPZATO

NDA NDA201848

Aug 18, 2023

IVRA

NDA NDA217110

Sources

References

[1]
ClinicalTrials.gov — 591 trial records for melphalan. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Alkeran drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — melphalan compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for melphalan. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA217110). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Alkeran. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Apotex Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AApotex Inc.

Patent Landscape[6]

Patent Cliff

May 28, 2030

Earliest patent expiration — generic entry possible after this date

Patent #Expires

11020363May 28, 2030

10864183May 28, 2030

10940128Jun 14, 2030

10369264Nov 7, 2032

10098997Nov 7, 2032

10 more patents

11633528Nov 7, 2032

11241522Nov 7, 2032

10569004Nov 7, 2032

11083831Dec 30, 2032

11833286Dec 30, 2032

10195334Jan 16, 2033

10040872Jan 30, 2034

9314561Feb 7, 2034

9707331Sep 17, 2034

10537520Jun 29, 2036

Alkeran

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q2 2028

Trials by Indication[1]

Multiple Myeloma46 trials

Lymphoma20 trials

Stem Cell Transplant9 trials

Neuroblastoma7 trials

Hematologic Malignancies6 trials

Primary Systemic Amyloidosis4 trials

Stem Cell Transplantation4 trials

Leukemia3 trials

Myelodysplastic Syndrome3 trials

Transplantation3 trials

Myelofibrosis3 trials

Germ Cell Tumor3 trials

Amyloidosis3 trials

Acute Myeloid Leukemia3 trials

Colorectal Cancer3 trials

Myeloma2 trials

Hematopoietic Stem Cell Transplant2 trials

Lenalidomide2 trials

Acute Lymphoblastic Leukemia2 trials

Melanoma2 trials

Lymphoid Malignancies2 trials

Chemotherapy2 trials

Mantle Cell Lymphoma2 trials

Ewing sarcoma2 trials

Breast Cancer2 trials

Myelodysplastic Syndromes2 trials

Bone Marrow Transplantation2 trials

Conditioning2 trials

Aplastic Anemia1 trial

Stage IV Ovarian Epithelial Cancer1 trial

Graft Versus Host Disease1 trial

Liver Cancer1 trial

TED1 trial

Autologous Hematopoietic Stem Cell Transplantation1 trial

Maintenance Therapy1 trial

High Risk1 trial

Exercise1 trial

Central Nervous System Lymphoma1 trial

Sickle Cell Disease1 trial

Infusion1 trial

Brain Cancer1 trial

Relapse1 trial

Stem Cell1 trial

Hematopoietic Cell Transplantation1 trial

Ocular Melanoma1 trial

Unilateral Retinoblastoma1 trial

Unresectable Cancer1 trial

Kidney Transplant1 trial

Metabolic Disease1 trial

Chronic Myelogenous Leukemia1 trial

Myeloid Neoplasm1 trial

Prostate Cancer1 trial

Toxicity1 trial

Memory1 trial

Metastatic Cancer1 trial

Anemia1 trial

Retinoblastoma1 trial

Hematopoietic Cell Transplant1 trial

Donor1 trial

Cutaneous T-cell lymphoma1 trial

Mesenchymal Stem Cells1 trial

Soft Tissue Sarcoma1 trial

Acute Leukemia1 trial

Langerhans Cell Histiocytosis1 trial

Patients With Solid Tumors1 trial

Myeloid Malignancies1 trial

AL amyloidosis1 trial

Chronic Lymphocytic Leukemia1 trial

Relapsed or Refractory Hematologic Malignancies1 trial

Malignancies1 trial

Recurrent or Refractory Solid Tumors1 trial

Peripheral Blood Stem Cell Transplantation1 trial